Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Consolidated Net Income (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Consolidated Net Income readings, the most recent being -$39.6 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 21.09% to -$39.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$149.9 million through Mar 2026, down 2.24% year-over-year, with the annual reading at -$143.0 million for FY2025, 0.08% changed from the prior year.
  • Consolidated Net Income hit -$39.6 million in Q1 2026 for Oric Pharmaceuticals, down from -$34.6 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at -$20.7 million in Q2 2022 and bottomed at -$39.6 million in Q1 2026.
  • Average Consolidated Net Income over 5 years is -$30.9 million, with a median of -$31.4 million recorded in 2023.
  • The largest annual shift saw Consolidated Net Income tumbled 50.76% in 2023 before it grew 12.68% in 2025.
  • Oric Pharmaceuticals' Consolidated Net Income stood at -$20.8 million in 2022, then tumbled by 50.76% to -$31.4 million in 2023, then dropped by 25.91% to -$39.6 million in 2024, then increased by 12.68% to -$34.6 million in 2025, then dropped by 14.67% to -$39.6 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Consolidated Net Income are -$39.6 million (Q1 2026), -$34.6 million (Q4 2025), and -$36.7 million (Q3 2025).